The ATS/ERS 2025 statement on interstitial pneumonia classification updates the 2013 statement, with insights on secondary ...

In the landscape of restorative dentistry, the transition from removable prosthetics like dentures and bridges to permanent, ...

The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic pulmonary fibrosis into its Biomarker Qualification Program, according to a press ...

Regarding the fire at the Ehome S apartment building in Long Truong ward, Ho Chi Minh City, which left a mother and her two ...

Chugai files regulatory application with MHLF for additional indication of Tecentriq to treat adjuvant therapy for MRD-positive bladder cancer: Tokyo Thursday, January 29, 2026, 0 ...

Previously, arsenic was used to kill severely inflamed bone marrow tissue when anesthesia was ineffective. However, due to its high toxicity and the risk of serious complications, this method is no ...

LANGHORNE, PA — PANTHERx Rare Pharmacy and Savara Inc. (Nasdaq: SVRA) announced an exclusive U.S. distribution agreement for MOLBREEVI, an investigational inhaled therapy under FDA review for a rare ...

Discover how a gingivectomy treats gum disease and improves aesthetics. Learn about the procedure, pain levels, and costs ...

Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and security agreement with Hercules Capital, Inc.

Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease that affects somewhere between 4 and 40 people per million worldwide. The condition causes substances such as fats and proteins to ...